Editorial Board About Us

Prostate-specific membrane antigen

All articles from this key word are listed below.

Volume 6, Supplement 10 Supplement

Overview of Prostate-Specific Membrane Antigen

Prostate cancer Angiogenesis Prostate-specific membrane antigen Monoclonal antibody

Volume 8, Supplement 2 Review Articles

Prostate Cancer: Epidemiology, Screening, and Biomarkers

16th International Prostate Cancer Update

Gerald W Chodak

Carcinoma of the prostate continues to be a major health problem in the United States. Beginning in 1988, a marked increase in detection of prostate cancer occurred due to the development of a test for prostate-specific antigen (PSA). Controversy exists, however, about the value of PSA as a tumor marker. Although it has prognostic significance both before and after definitive therapy for prostate cancer, it is unclear whether routine PSA screening will translate into a survival advantage for patients. Because of its limitations, PSA may not ultimately be a good enough marker to be used as a screening tool. However, molecular biology has led to a rapid rise in the number of potential new prostate tumor markers, which may eventually overcome the weaknesses of PSA. Considerable progress has occurred in the diagnosis and management of prostate cancer: more is understood about the risk factors for the disease, possible ways to prevent it, and new ways to diagnose and monitor it. These developments have already translated into better patient care, while also identifying where further improvements are needed. [Rev Urol. 2006;8(suppl 2):S3-S8]

Prostate cancer Prostate-specific antigen Biomarkers Prostate-specific membrane antigen Prostate-specific antigen doubling time

Volume 8, Supplement 1 Review Articles

The Emergence of Radioimmunoscintigraphy for Prostate Cancer

Prostate Cancer Imaging

David G McLeod Thomas E Keane Inger L Rosner M Scott Wingo

The ability to label tissue-specific antibodies has long been of interest for improving detection and guidance for therapeutic applications. The most studied target for prostate cancer is the prostate-specific membrane antigen, which is upregulated in prostate cancer, hormone-refractive disease, and prostate cancer metastases. Investigations using radioimmunoscintigraphy with the radiolabeled 7E11 antibody capromab pendetide have significantly improved sensitivity for prostate cancer detection compared with standard cross-sectional imaging, based on tissue confirmation of pathologic results. Over the past 5 years, significantly greater image resolution from improved camera technology and the use of co-registration to fuse functional and anatomic (computerized tomography and magnetic resonance imaging) images have dramatically enhanced prostate cancer localization. Outcomes data from several sources have spurred a resurgence in interest in this imaging modality. [Rev Urol. 2006;8(suppl 1):S20-S28]

Prostate cancer ProstaScint Prostate-specific membrane antigen Radioimmunoscintigraphy Capromab pendetide Image co-registration Lymph node metastasis